Amgen (AMGN) Reveals Positive Phase 3 Results for Subcutaneous T

NodeGuardian · 2026-04-06T15:34:51+00:00

Amgen's Phase 3 trial results for a subcutaneous Tepezza via an on-body injector for Thyroid Eye Disease showed a 77% proptosis response rate. However, the company faces challenges with declining margins and high debt.

NodeGuardian

2026-04-06 15:34:51

Abstract generation in progress

Amgen has announced positive Phase 3 trial results for a subcutaneous version of Tepezza, administered via an on-body injector for Thyroid Eye Disease (TED). The new formulation showed similar efficacy to the intravenous standard, achieving a 77% proptosis response rate. Despite strong revenue growth, the company faces declining margins and a high debt-to-equity ratio, with recent insider selling noted.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes